Multiple Helicobacter pylori enzymes and proteins

Helicobacter pylori is a Gram-negative, microaerophilic bacterium that colonizes the human gastric mucosa, leading to chronic gastritis, peptic ulcer disease, and an increased risk of gastric adenocarcinoma (NIH, 2023). The target designation "Multiple Helicobacter pylori enzymes and proteins" refers to the diverse array of bacterial components targeted by current and emerging antimicrobial therapies. A primary target is the enzyme urease, which allows the bacterium to survive the acidic stomach environment by catalyzing the hydrolysis of urea into ammonia and carbon dioxide (UniProt, 2024). Other critical targets include penicillin-binding proteins (PBPs) involved in cell wall synthesis, the 30S and 50S ribosomal subunits responsible for protein translation, and DNA gyrase, which is essential for DNA replication (StatPearls, 2024). Virulence factors such as the vacuolating cytotoxin A (VacA) and the cytotoxin-associated gene A (CagA) protein are also significant as they modulate host immune responses and promote oncogenesis (PubMed, 2022). Eradication of the infection typically requires multi-drug regimens, such as bismuth-based quadruple therapy or clarithromycin-based triple therapy, to address the challenges of the gastric environment and the rising prevalence of antibiotic resistance (WHO, 2021). The identification and characterization of these multiple targets are essential for developing novel therapeutic strategies to combat multi-drug resistant strains of H. pylori (Nature Reviews Microbiology, 2023).

Other names

Helicobacter pylori proteomeH. pylori drug targetsAnti-Helicobacter pylori targets

Inhibition of bacterial cell wall synthesis, inhibition of protein synthesis, inhibition of DNA replication, and disruption of bacterial metabolism.